Literature DB >> 27365077

Prevention of surgical site sternal infections in cardiac surgery: a two-centre prospective randomized controlled study.

Christoph Schimmer1, Justus Gross2, Elena Ramm2, Björn-Carsten Morfeld1, Grischa Hoffmann2, Bernd Panholzer2, Jürgen Hedderich3, Rainer Leyh1, Jochen Cremer2, Rainer Petzina4.   

Abstract

OBJECTIVES: Surgical site infection (SSI) of the sternum is a devastating complication in cardiac surgery. The aim of this prospective randomized controlled two-centre clinical study was to compare the use of a gentamicin-collagen sponge (Genta-Coll® resorb) and of a cyanoacrylate-based microbial skin sealant (InteguSeal®) on the SSI rate of the sternum.
METHODS: We analysed data from 996 consecutive patients following isolated coronary artery bypass grafting between 2012 and 2014. The patients were randomized into three groups: standard group (S-group), Genta-Coll group (G-group) and InteguSeal group (I-group). The primary study end-point was to analyse the incidence of superficial and deep sternal SSI. The secondary study end-point was to determine independent risk factors for an increased SSI rate.
RESULTS: Of the 996 patients investigated, 332 patients were in S-group, 336 patients in G-group and 328 patients in I-group. The mean age was 67.7 ± 9.4 years, 18.6% were women and the overall SSI rate was 6.2% with 2.2% deep sternal wound infections. SSI rates were 8.3% (S-group), 5.4% (G-group) and 4.9% (I-group) (P 0.16). Multiple regression analysis demonstrated a preoperative body mass index (BMI) of >30 kg/m2 (P 0.047), re-thoracotomy for postoperative bleeding (P < 0.001) and sternum instability (P < 0.001) as independent predictors for an increased SSI rate.
CONCLUSIONS: The application of InteguSeal® or Genta-Coll® resorb had no significant influence on the incidence of the sternal SSI rate in 996 consecutive cardiac surgery patients but demonstrated a trend towards a benefit from using these prophylactic approaches. Multiple regression analysis demonstrated a preoperative BMI of >30 kg/m2, re-thoracotomy for bleeding and sternum instability as independent predictors for an increased sternal SSI rate.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  CABG; Cardiac surgery; Mediastinitis; Surgical site infection

Mesh:

Substances:

Year:  2016        PMID: 27365077     DOI: 10.1093/ejcts/ezw225

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Gentamicin submucosal lavage during peroral endoscopic myotomy (POEM): a retrospective analysis.

Authors:  Julia Bayer; Zuzana Vackova; Hana Svecova; Petr Stirand; Julius Spicak; Jan Martinek
Journal:  Surg Endosc       Date:  2017-06-27       Impact factor: 4.584

2.  The Modified Sternoplasty: A Novel Surgical Technique for Treating Mediastinitis.

Authors:  Erez Kachel; Mattan Arazi; Liza Grosman-Rimon; Shachar Yehezkeel; Jordan Rimon; Jacob Gohari; Amihay Shinfeld; Leonid Sternik; Ehud Raanani; Yaron Moshkovitz
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-04-29

3.  Risk factors of nosocomial infection after cardiac surgery in children with congenital heart disease.

Authors:  Xindi Yu; Maolin Chen; Xu Liu; Yiwei Chen; Zedong Hao; Haibo Zhang; Wei Wang
Journal:  BMC Infect Dis       Date:  2020-01-21       Impact factor: 3.090

4.  The impact of closed incision negative pressure therapy on prevention of median sternotomy infection for high risk cases: a single centre retrospective study.

Authors:  Rona Lee Suelo-Calanao; Richard Thomson; Maxine Read; Euan Matheson; Emmanuel Isaac; Mubarak Chaudhry; Mahmoud Loubani
Journal:  J Cardiothorac Surg       Date:  2020-08-19       Impact factor: 1.637

5.  A Preliminary Exploration of the Efficacy of Gentamicin Sponges in the Prevention and Treatment of Wound Infections.

Authors:  Yongduo Li; Junlin Zhou
Journal:  Infect Drug Resist       Date:  2021-07-08       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.